Eribulin mesylate in breast cancer. - Wikidata - wikimedia - TriplyDB

Eribulin mesylate in breast cancer.

Eribulin mesylate in breast cancer.

http://www.wikidata.org/entity/Q54694130

about

Eribulin disrupts EB1-microtubule plus-tip complex formation

P2860

Q36187429-750E7FA2-541C-4846-A409-4589CC66C05C

P2860

Eribulin mesylate in breast cancer.

http://www.wikidata.org/entity/Q54694130

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Eribulin mesylate in breast cancer.

@en

Eribulin mesylate in breast cancer.

@nl

type

label

Eribulin mesylate in breast cancer.

@en

Eribulin mesylate in breast cancer.

@nl

prefLabel

Eribulin mesylate in breast cancer.

@en

Eribulin mesylate in breast cancer.

@nl

P1433

Q54694130-1DBA7727-BE48-42B3-ADAB-C42869E0C0D3

P1476

Q54694130-60192907-133F-4899-B1BB-7618AAA866C3

P2093

Q54694130-8E6ACBC5-55D1-47C8-BC3F-65FB3C21D543

Q54694130-A350E3B5-521B-468E-B74F-25A8F1154A3A

P2860

Q54694130-28ADBB0C-F8D7-4075-9E63-16836D37ADA9

Q54694130-559097CC-DFEF-4975-8572-4D8ABD1FFED6

Q54694130-56BA8AD9-02B7-47C1-B5E9-95CA0BB82B2B

Q54694130-56F29847-B1BB-41DC-87D3-5840BDAF05D8

Q54694130-60449A92-8F63-4B70-A7A2-DEF29794C9C3

Q54694130-631E5E61-AA6C-46AA-9A63-AB420EE5490A

Q54694130-66FF2A38-882F-4D9F-B9BA-84FD18ADE1BC

Q54694130-76BA7BD8-79DC-4B4A-9C04-4383D9A7E036

Q54694130-7A2EAF75-DF7F-491C-A79C-7395284167F4

Q54694130-8D6128BE-2B2D-461F-8626-215FC392728F

P304

Q54694130-819581C0-8C47-4FB8-B236-1D3433D699F7

P31

Q54694130-5E57E14A-F7AA-4868-A40D-A28DF20552BC

P356

Q54694130-9E622CD5-ED69-4F2E-BBB6-F5D5D9916306

P433

Q54694130-373CB017-4933-441F-8DF5-CBB9BF5C64ED

P478

Q54694130-92955E42-D86A-47F5-9BDB-21E7083F87D4

P50

Q54694130-403770EF-2FB2-4D0F-A396-8218653888C6

P577

Q54694130-45E2937E-B505-4454-ACA8-4855E9BA7314

P698

Q54694130-8738F65B-4DBB-4E2D-8982-C867F18DE351

P356

P1433

P1476

Eribulin mesylate in breast cancer.

@en

P2093

Helena Verdaguer

http://www.w3.org/2001/XMLSchema#string

Idoia Morilla

http://www.w3.org/2001/XMLSchema#string

P2860

Microtubules as a target for anticancer drugs

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Microtubule active agents: beyond the taxane frontier.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin.

Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice.

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

P304

517-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/WHE.13.61

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Ander Urruticoechea

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24161305

http://www.w3.org/2001/XMLSchema#string